Cara Therapeutics and Vifor Pharma announced that the U.S. Food and Drug Administration has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis . KORSUVA injection is a first-in-class kappa opioid receptor (KOR) agonist that targets the body’s peripheral nervous system.
- Read more about Cara Therapeutics and Vifor Pharma announce USFDA approval of KORSUVA injection for the treatment of moderate-to-severe pruritus in hemodialysis patients
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/cara-therapeutics-and-vifor-pharma-announce-usfda-approval-of-korsuva-injection-for-the-treatment-of-moderate-to-severe-pruritus-in-hemodialysis-patients
No comments:
Post a Comment